Key facts
- Revelyx Bio’s last known valuation is $109.5M (Jan 2026).
- It has raised $10.4M; the latest was Early Stage VC ($10.0M) in Jan 2026.
- Notable investors include NRL Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Revelyx Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Revelyx Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Revelyx Bio
Developer of a botulinum toxin liquid formulation designed to bring a new anti-aging and medical experience characterized by efficacy. The company's formulation is low immunogenicity, overcomes drug resistance, has precise targeting, and user-friendly.
- Sector
- Healthcare
- HQ
- DE
- Founded
- 2025
- Ownership
- Privately Held (backing)
Revelyx Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revelyx Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revelyx Bio in its N-PORT filings yet. We sweep new filings monthly.